Samsrita Labs Acquires Cancer Drug Patent, Reports Q2 FY26 Results
Samsrita Labs Limited reported a consolidated loss for Q2 FY26, with a net loss of Rs 454.77 lakhs. The company acquired a cancer drug patent for Rs 2 crores and took a 28.62% stake in QROPS Advisory Services. It raised funds through a preferential issue of equity shares and made financial adjustments including write-offs of advances and provisions for bad debts. Despite current losses, management views recent strategic moves as positioning the company for future growth in the healthcare sector.
*this image is generated using AI for illustrative purposes only.
Samsrita Labs Limited , a healthcare sector company, has announced its unaudited financial results for the quarter and half-year ended September 30, 2025, along with significant corporate actions that could shape its future trajectory.
Key Highlights
- Acquisition of a cancer drug patent for Rs 2 crores
- Preferential issue of equity shares raising funds and acquiring stake in QROPS Advisory Services
- Write-off of advances and provision for bad debts
Financial Performance
The company reported a consolidated loss for the quarter, primarily due to increased expenses and one-time write-offs. Here's a breakdown of the key financial metrics:
| Particulars (in Rs. Lakhs) | Q2 FY26 | H1 FY26 |
|---|---|---|
| Revenue from Operations | 0.00 | 0.00 |
| Total Expenses | 493.50 | 521.16 |
| Net Loss | 454.77 | 460.45 |
| Earnings Per Share (Basic) | (2.00) | (2.02) |
Strategic Acquisitions and Investments
Samsrita Labs has made significant moves to strengthen its position in the healthcare sector:
Patent Acquisition: The company purchased a patent on "Drug Conjugated Ultra-Small Gold Nanoparticle for Effective Killing of Drug-Resistant Cancer Cells" from Centre for Liver Research and Diagnostics for Rs 2 crores plus taxes. This acquisition was funded through the adjustment of existing deposits.
Stake in QROPS Advisory Services: Samsrita Labs acquired a 28.62% stake in QROPS Advisory Services Private Limited through a share swap arrangement. This strategic move has resulted in QROPS becoming an associate company, with its profits now incorporated into Samsrita's consolidated financial statements.
Capital Raising and Share Issuance
The company has raised funds through a preferential issue of equity shares:
- Issued 33.91 lakh equity shares at Rs 10 each to non-promoters
- Issued 45.50 lakh equity shares to promoters of QROPS Advisory Services Pvt Ltd as part of the share-swap arrangement
Financial Adjustments
Samsrita Labs has taken steps to clean up its balance sheet:
- Wrote off advances of Rs 2.59 crores with Centre for Liver Research and Diagnostics against COVID-19 related pending claims
- Provided Rs 2.09 crores as provision for bad debt from debtor Mangal Savitri Bizcon Private Limited
Management Commentary
K. Krishnam Raju, Chairman & Whole-time Director of Samsrita Labs Limited, stated, "While our financial results for this quarter reflect some one-time adjustments, we believe the strategic moves we've made, particularly the acquisition of the cancer drug patent and our investment in QROPS Advisory Services, position us well for future growth in the healthcare sector."
Outlook
The acquisition of the cancer drug patent may potentially open new avenues for Samsrita Labs in the oncology space. Additionally, the strategic investment in QROPS Advisory Services could diversify the company's revenue streams. However, investors should note that the company is currently operating at a loss, and the success of these initiatives will be crucial for its future performance.
As Samsrita Labs continues to navigate the challenges in the healthcare sector, stakeholders will be watching closely to see how these strategic moves translate into financial performance in the coming quarters.
Historical Stock Returns for Samsrita Labs
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| +7.00% | +5.92% | +2.30% | +16.27% | -9.23% | -56.33% |
16
